BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:50 PM
 | 
Apr 21, 2010
 |  BC Extra  |  Company News

Genzyme expects $175M fine, further delays

Genzyme Corp. (NASDAQ:GENZ) expects a $175 million fine based on FDA's draft Consent Decree regarding deficiencies at the company's Allston, Mass., manufacturing plant. Genzyme also could incur a penalty of 18.5% of revenues on any products that are manufactured at the plant after FDA's deadlines to move fill/finish operations from...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >